Evidence map›Paper›PMID 36717723›Full record

ArticleNature immunology2023

A patient-centric modeling framework captures recovery from SARS-CoV-2 infection.

Hélène Ruffieux, Aimee L Hanson, Samantha Lodge, Nathan G Lawler, Luke Whiley, Nicola Gray, Tui H Nolan, Laura Bergamaschi, Federica Mescia, Lorinda Turner and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Long COVID Is Not a Functional Neurologic Disorder.Journal of personalized medicine · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Hélène RuffieuxMRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK. helene.ruffieux@mrc-bsu.cam.ac.uk.ORCID http://orcid.org/0000-0002-7113-2540
Aimee L HansonCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Samantha LodgeAustralian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.
Nathan G LawlerAustralian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.ORCID http://orcid.org/0000-0001-9649-425X
Luke WhileyAustralian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.
Nicola GrayAustralian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.ORCID http://orcid.org/0000-0002-0094-5245
Tui H NolanMRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
Laura BergamaschiCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Federica MesciaCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-2759-4027
Lorinda TurnerCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Aloka de SaCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Victoria S PellyCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) BioResource COVID-19 Collaboration
Prasanti KotagiriCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-9806-4349
Nathalie KingstonDepartment of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
John R BradleyDepartment of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Elaine HolmesAustralian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.ORCID http://orcid.org/0000-0002-0556-8389
Julien WistAustralian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.ORCID http://orcid.org/0000-0002-3416-2572
Jeremy K NicholsonAustralian National Phenome Centre, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.ORCID http://orcid.org/0000-0002-8123-8349
Paul A LyonsCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-7035-8997
Kenneth G C SmithCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.
Sylvia RichardsonMRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.ORCID http://orcid.org/0000-0003-1998-492X
Glenn R BantugDepartment of Biomedicine, University and University Hospital Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-2253-6028
Christoph HessCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK. ch818@cam.ac.uk.ORCID http://orcid.org/0000-0003-0364-8825

Funding

Medical Research Council MR/L019027Medical Research Council MR/L019027/1Medical Research Council MR/W018861/1Wellcome Trust 200871Wellcome Trust 200871/Z/16/ZWellcome Trust 200871/Z/16/ ZWellcome Trust 219506/Z/19/Z
6 · The paper itself

Abstract

The biology driving individual patient responses to severe acute respiratory syndrome coronavirus 2 infection remains ill understood. Here, we developed a patient-centric framework leveraging detailed longitudinal phenotyping data and covering a year after disease onset, from 215 infected individuals with differing disease severities. Our analyses revealed distinct 'systemic recovery' profiles, with specific progression and resolution of the inflammatory, immune cell, metabolic and clinical responses. In particular, we found a strong inter-patient and intra-patient temporal covariation of innate immune cell numbers, kynurenine metabolites and lipid metabolites, which highlighted candidate immunologic and metabolic pathways influencing the restoration of homeostasis, the risk of death and that of long COVID. Based on these data, we identified a composite signature predictive of systemic recovery, using a joint model on cellular and molecular parameters measured soon after disease onset. New predictions can be generated using the online tool http://shiny.mrc-bsu.cam.ac.uk/apps/covid-19-systemic-recovery-prediction-app , designed to test our findings prospectively.

Indexed as

COVID-19HumansKynureninePatient-Centered CarePost-Acute COVID-19 SyndromeSARS-CoV-2Kynurenine

Identifiers

PMID36717723
PMCPMC9892000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.